These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 25811748

  • 1. Cultural preferences and limited public resources influence the spectrum of thalassemia in Egypt.
    Adly AA, Ebeid FS.
    J Pediatr Hematol Oncol; 2015 May; 37(4):281-4. PubMed ID: 25811748
    [Abstract] [Full Text] [Related]

  • 2. Major risk of blood transfusion in hemolytic anemia patients.
    Omar N, Salama K, Adolf S, El-Saeed GS, Abdel Ghaffar N, Ezzat N.
    Blood Coagul Fibrinolysis; 2011 Jun; 22(4):280-4. PubMed ID: 21508832
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prevalence of HBV and HCV infection among multi-transfused Egyptian thalassemic patients.
    Mansour AK, Aly RM, Abdelrazek SY, Elghannam DM, Abdelaziz SM, Shahine DA, Elmenshawy NM, Darwish AM.
    Hematol Oncol Stem Cell Ther; 2012 Jun; 5(1):54-9. PubMed ID: 22446611
    [Abstract] [Full Text] [Related]

  • 5. Prevalence of hepatitis C infection among children with β-thalassaemia major in Mid Delta, Egypt: a single centre study.
    El-Shanshory MR, Kabbash IA, Soliman HH, Nagy HM, Abdou SH.
    Trans R Soc Trop Med Hyg; 2013 Apr; 107(4):224-8. PubMed ID: 23343507
    [Abstract] [Full Text] [Related]

  • 6. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE, Edelsberg J, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [Abstract] [Full Text] [Related]

  • 7. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [Abstract] [Full Text] [Related]

  • 8. Thalassemia treatment and prevention in Uva Province, Sri Lanka: a public opinion survey.
    Mudiyanse RM.
    Hemoglobin; 2006 Apr; 30(2):275-89. PubMed ID: 16798653
    [Abstract] [Full Text] [Related]

  • 9. Abnormal glucose tolerance in Egyptian beta-thalassemic patients: possible association with genotyping.
    Khalifa AS, Salem M, Mounir E, El-Tawil MM, El-Sawy M, Abd Al-Aziz MM.
    Pediatr Diabetes; 2004 Sep; 5(3):126-32. PubMed ID: 15450007
    [Abstract] [Full Text] [Related]

  • 10. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 11. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine.
    Ehlers KH, Giardina PJ, Lesser ML, Engle MA, Hilgartner MW.
    J Pediatr; 1991 Apr; 118(4 Pt 1):540-5. PubMed ID: 2007928
    [Abstract] [Full Text] [Related]

  • 12. Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.
    Hatzipantelis ES, Karasmanis K, Perifanis V, Vlachaki E, Tziomalos K, Economou M.
    Hemoglobin; 2014 Apr; 38(2):111-4. PubMed ID: 24351163
    [Abstract] [Full Text] [Related]

  • 13. Antibody titration and immune response of Iranian beta-thalassemic patients to hepatitis B virus vaccine (booster effect).
    Azarkeivan A, Karimi G, Shaiegan M, Maghsudlu M, Tabbaroki A.
    Pediatr Hematol Oncol; 2009 Jun; 26(4):195-201. PubMed ID: 19437322
    [Abstract] [Full Text] [Related]

  • 14. Red cell alloimmunization and infectious marker status (human immunodeficiency virus, hepatitis B virus and hepatitis C virus) in multiply transfused thalassemia patients of North India.
    Makroo RN, Arora JS, Chowdhry M, Bhatia A, Thakur UK, Minimol A.
    Indian J Pathol Microbiol; 2013 Jun; 56(4):378-83. PubMed ID: 24441225
    [Abstract] [Full Text] [Related]

  • 15. Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.
    Karakukcu C, Karakukcu M, Unal E, Patiroglu T, Ozdemir MA, Torun YA, Tang PH.
    Hemoglobin; 2012 Jun; 36(3):219-29. PubMed ID: 22483337
    [Abstract] [Full Text] [Related]

  • 16. Chelation therapy in beta-thalassemia major. III. The role of splenectomy in achieving iron balance.
    Graziano JH, Piomelli S, Hilgartner M, Giardina P, Karpatkin M, Andrew M, LoIacono N, Seaman C.
    J Pediatr; 1981 Nov; 99(5):695-9. PubMed ID: 7299540
    [Abstract] [Full Text] [Related]

  • 17. Quality of Life Outcomes in a Pediatric Thalassemia Population in Egypt.
    Adam S, Afifi H, Thomas M, Magdy P, El-Kamah G.
    Hemoglobin; 2017 Jan; 41(1):16-20. PubMed ID: 28440111
    [Abstract] [Full Text] [Related]

  • 18. [Chelating therapy in beta-thalassemia].
    Musumeci S, Romeo MA, Di Gregorio F, Schiliró G, Russo G.
    Pediatr Med Chir; 1982 Jan; 4(1-2):55-9. PubMed ID: 7111040
    [Abstract] [Full Text] [Related]

  • 19. Pilot study on the "quality of life" as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan.
    Kuo HT, Tsai MY, Peng CT, Wu KH.
    Hemoglobin; 2006 Jan; 30(2):291-9. PubMed ID: 16798654
    [Abstract] [Full Text] [Related]

  • 20. Chelation therapy and ferritin levels in patients with homozygous beta-thalassemia.
    Kattamis C, Lagos P, Langona E.
    Prog Clin Biol Res; 1979 Jan; 34():351-9. PubMed ID: 531060
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.